A revised international staging system (R-ISS) from the IMWG provides the most up-to-date tool for stratifying patient risk based on prognosis. 

The Durie-Salmon Staging System is another staging system that correlates the amount of myeloma to the damage it has caused, such as bone disease or .


Careful testing after each cycle of treatment will indicate whether the treatment is working or not. If is slow and side-effects are manageable, additional therapy should be considered. Thus, accurate assessment is important. As shown below, there is a correlation between test results and the number of myeloma cells. 

IMWG response criteria - if the is less than desired, the practitioner and patient should discuss whether to watch and wait, switch therapies, or continue with a maintenance dose.

Related Content

The Advanced Practitioner's Guide to
JADPRO Vol. 7 | Supplement 1 | March 2016
Updates in the Diagnosis and Monitoring of Multiple Myeloma

Comprised of oncology-certified nurses, the Nurse Leadership Board has extensive knowledge of the treatment and care landscape. These resources were developed by their team.

Last Medical Review: August 1, 2019

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.